Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2003 1
2011 3
2012 3
2013 7
2014 8
2015 10
2016 8
2017 9
2018 15
2019 23
2020 25
2021 25
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

126 results
Results by year
Filters applied: . Clear all
Page 1
STING pathway agonism as a cancer therapeutic.
Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF. Flood BA, et al. Among authors: luke jj. Immunol Rev. 2019 Jul;290(1):24-38. doi: 10.1111/imr.12765. Immunol Rev. 2019. PMID: 31355488 Free PMC article. Review.
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL Jr, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. Grasso CS, et al. Among authors: luke jj. Cancer Cell. 2020 Oct 12;38(4):500-515.e3. doi: 10.1016/j.ccell.2020.08.005. Epub 2020 Sep 10. Cancer Cell. 2020. PMID: 32916126 Free PMC article.
Toll-Like Receptor 9 Agonists in Cancer.
Karapetyan L, Luke JJ, Davar D. Karapetyan L, et al. Among authors: luke jj. Onco Targets Ther. 2020 Oct 9;13:10039-10060. doi: 10.2147/OTT.S247050. eCollection 2020. Onco Targets Ther. 2020. PMID: 33116588 Free PMC article. Review.
Considering adjuvant therapy for stage II melanoma.
Poklepovic AS, Luke JJ. Poklepovic AS, et al. Among authors: luke jj. Cancer. 2020 Mar 15;126(6):1166-1174. doi: 10.1002/cncr.32585. Epub 2019 Dec 23. Cancer. 2020. PMID: 31869447 Free PMC article. Review.
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, M Eggermont AM. Luke JJ, et al. Future Oncol. 2020 Jan;16(3):4429-4438. doi: 10.2217/fon-2019-0666. Epub 2019 Dec 24. Future Oncol. 2020. PMID: 31870188 Free article.
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Heinzerling L, et al. Among authors: luke jj. J Immunother Cancer. 2016 Aug 16;4:50. doi: 10.1186/s40425-016-0152-y. eCollection 2016. J Immunother Cancer. 2016. PMID: 27532025 Free PMC article.
126 results